Download PDF
Pneumologie 2020; 74(07): 423-428
DOI: 10.1055/a-1199-2167
Fallbericht

ECMO als Therapie des schweren Lungenversagens bei COVID-19

ECMO Therapy in a Case of Severe ARDS Related to COVID-19
M. Schmauss
1   Klinik für Anästhesiologie, Intensiv-, Notfall- und Schmerzmedizin, EVK Herne, Herne
,
E. Müller
1   Klinik für Anästhesiologie, Intensiv-, Notfall- und Schmerzmedizin, EVK Herne, Herne
,
M. Schwamborn
2   Thoraxzentrum Ruhrgebiet, Klink für Innere Medizin, Pneumologie und Infektiologie, EVK Herne, Herne
,
C. Giesa
2   Thoraxzentrum Ruhrgebiet, Klink für Innere Medizin, Pneumologie und Infektiologie, EVK Herne, Herne
,
S. Ewig
3   Klinken für Innere Medizin, Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum, Bochum
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Wir berichten über den Fall einer 60-jährigen Patientin mit fortgeschrittenem schwerem Lungenversagen bei COVID-19-assoziierter Pneumonie. Die Patientin erhielt zuerst 2 Tage eine (Highflow-)Sauerstoff-Therapie (HFNC) und CPAP, anschließend musste sie intubiert und invasiv beatmet werden. Nach dem Scheitern einer invasiven Beatmung mit schwerster Hypoxämie erfolgte der Anschluss an eine vv-ECMO. Diese wurde über 24 Tage durchgeführt. Die prognostischen Parameter zeigten ab Tag 14 eine günstige Tendenz. Nach Beendigung der ECMO und insgesamt 11 Tagen stundenweiser assistierter Beatmung über Tracheostoma und Sauerstoff (1 l/min) konnte die Patientin in die Rehabilitationsbehandlung verlegt werden. Die letzte Röntgenthoraxaufnahme zeigte eine nahezu vollständige Rückbildung der initialen ausgedehnten beidseitigen Verschattungen. Unser Fall zeigt, dass auch nach einer prolongierten ECMO-Therapie eine Ausheilung der schweren COVID-assoziierten Lungenschäden möglich ist.

Abstract

We report the case of a 60-year old female patient with advanced severe lung injury as a consequence of COVID-19-pneumonia. The patient was initially treated with highflow oxygen via nasal cannula (HFNC) and CPAP for two days but had to be intubated and mechanically ventilated. After failure of mechanical ventilation because of persistant severe hypoxemia treatment was switched to ECMO which was applicated for 24 days. Prognostic parameters indicated a favourable trend after day 14. After discontinuation of ECMO and 11 days of intermittent assisted ventilation via tracheostoma and low dose oxygen (1 l/min), the patient could be transferred to rehabilitation. The last chest radiograph prior to transferral revealed a nearly complete resolution of bilateral pulmonary infiltrates. Our case demonstrates that severe COVID-19-associated lung injury can be reversible even after prolonged ECMO.



Publication History

Received: 13 June 2020

Accepted: 15 June 2020

Article published online:
16 July 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
    CrossrefPubMedGoogle Scholar
  • 2 ICNARC. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports 17.4.2020
    PubMed
  • 3 Richardson S, Hirsch JS, Narasimhan M. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; e206775
    PubMedGoogle Scholar
  • 4 Docherty AB, Harrison EM, Green CA. et al. ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985
    PubMedGoogle Scholar
  • 5 Wang Y, Lu X, Chen H. et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med 2020; DOI: 10.1164/rccm.202003-0736LE.
    CrossrefPubMedGoogle Scholar
  • 6 Chua F, Armstrong-James D, Desai SR. et al. The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respir Med 2020; 8: 438-440
    CrossrefPubMedGoogle Scholar
  • 7 Wu C, Chen X, Cai Y. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With CoronavirusDisease 2019 Pneumonia in Wuhan, China. JAMA internal medicine 2020; DOI: 10.1001/jamainternmed.2020.0994.
    CrossrefPubMedGoogle Scholar
  • 8 Mascheroni D, Kolobow T, Fumagalli R. et al. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. Intensive Care Med 1988; 15: 8-14
    CrossrefPubMedGoogle Scholar
  • 9 Carteaux G, Millán-Guilarte T, De Prost N. et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. Crit Care Med 2016; 44: 282-290
    PubMedGoogle Scholar
  • 10 Winck JC, Ambrosino N. COVID-19 pandemic and noninvasive respiratory management: every Goliath needs a David. An evidence-based evaluation of problems. Pulmonology 2020; DOI: 10.1016/j.pulmoe.2020.04.013.
    CrossrefPubMedGoogle Scholar
  • 11 Patel BK, Wolfe KS, Pohlman AS. et al. Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 2016; 315: 2435-2441
    CrossrefPubMedGoogle Scholar
  • 12 Grieco DL, Menga LS, Raggi V. et al. Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med 2020; 201: 303-312
    CrossrefPubMedGoogle Scholar
  • 13 Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA 2020; DOI: 10.1001/jama.2020.6825.
    CrossrefPubMedGoogle Scholar
  • 14 Gattinoni L, Chiumello D, Caironi P. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med 2020; 46: 1099-1102 DOI: 10.1007/s00134-020-06033-2.
    CrossrefPubMedGoogle Scholar
  • 15 Gattinoni L, Coppola S, Cressoni M. et al. COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2020; 201: 1299-1300
    CrossrefPubMedGoogle Scholar
  • 16 Hong X, Xiong J, Feng Z. et al. Extracorporeal Membrane Oxygenation (ECMO): Does It Have a Role in the Treatment of Severe COVID-19?. Int J Infect Dis 2020; 94: 78-80
    CrossrefPubMedGoogle Scholar
  • 17 Li X, Guo Z, Li B. et al. Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China. ASAIO J 2020; 66: 475-481
    CrossrefPubMedGoogle Scholar
  • 18 Hartman ME, Hernandez RA, Patel K. et al. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support. ASAIO J 2020; 66: 603-606
    CrossrefPubMedGoogle Scholar
  • 19 Schaller T, Hirschbühl K, Burkhardt K. et al. Postmortem Examination of Patients With COVID-19. JAMA 2020; e208907
    PubMedGoogle Scholar
  • 20 Giosa L, Busana M, Pasticci I. et al. Mechanical power at a glance: a simple surrogate for volume-controlled ventilation. Intensive Care Med Exp 2019; 7: 61 DOI: 10.1186/s40635-019-0276-8.
    CrossrefPubMedGoogle Scholar
  • 21 Copin MC, Parmentier E, Duburcq T. et al. Lille COVID-19 ICU and Anatomopathology Group. Time to Consider Histologic Pattern of Lung Injury to Treat Critically Ill Patients With COVID-19 Infection. Intensive Care Med 2020; DOI: 10.1007/s00134-020-06057-8.
    CrossrefPubMedGoogle Scholar
  • 22 Ramanathan K, Antognini D, Combes A. et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020; 8: 518-526
    CrossrefPubMedGoogle Scholar